Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL
Abstract
Recently published European Society for Medical Oncology (ESMO) guidelines recommend ibrutinib as front-line treatment in fit patients with IGHV-unmutated TP53-wild-type chronic lymphocytic leukemia (CLL), with graded evidence (I, A).1Eichhorst B. Robak T. Montserrat E. et al.Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021; 32: 23-33Abstract Full Text Full Text PDF PubMed...
Paper Details
Title
Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL
Published Date
Nov 1, 2021
Journal
Volume
32
Issue
11
Pages
1442 - 1443
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History